Akebia Therapeutics Inc. buy BTIG Research
Start price
29.11.23
/
50%
€0.92
Target price
29.11.24
€3.64
Performance (%)
-5.42%
Price
03.07.24
€0.87
Summary
This prediction is currently active. With a performance of -5.42%, the BUY prediction by BTIG_Research is trending in the wrong direction. This prediction currently runs until 29.11.24. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Akebia Therapeutics Inc. | -7.086% | -7.086% |
iShares Core DAX® | 1.395% | -0.696% |
iShares Nasdaq 100 | 2.287% | 7.501% |
iShares Nikkei 225® | 1.617% | 2.769% |
iShares S&P 500 | 0.659% | 4.280% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat